Stanford Launches Trial Of NeuroPace’s Responsive Neuromodulation To Stop Overeating
The DBSLOC trial will study the feasibility of using NeuroPace’s RNS responsive neuromodulation system to stimulate the nucleus accumbens in order to stop “loss-of-control” eating in people with treatment-refractory obesity, especially those who have failed to respond adequately to gastric bypass surgery.
You may also be interested in...
While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.
Edwards Lifesciences is ramping up US commercialization of its Pascal Precision mitral valve transcatheter edge-to-edge repair device, the first US competitor for Abbott’s MitraClip. The FDA approved Pascal Precision earlier than the company expected, based on results of the CLASP IID trial.